Characteristics of Fecal Microbiota Transplantation Use in Inflammatory Bowel Disease Cohort.
Crohn’s disease
fecal microbiota transplant
inflammatory bowel disease
ulcerative colitis
Journal
Crohn's & colitis 360
ISSN: 2631-827X
Titre abrégé: Crohns Colitis 360
Pays: England
ID NLM: 101752188
Informations de publication
Date de publication:
Apr 2020
Apr 2020
Historique:
received:
09
11
2019
revised:
06
05
2020
accepted:
15
01
2020
entrez:
19
5
2020
pubmed:
19
5
2020
medline:
19
5
2020
Statut:
ppublish
Résumé
There is a growing interest in the role of gut bacteria in a number of diseases and an emerging hypothesis that inflammatory bowel disease (IBD) is triggered by microbial dysbiosis in genetically susceptible individuals. Currently, fecal microbiota transplantation (FMT) is utilized for the treatment of Patients enrolled in the IBD Partners cohort were offered the opportunity to complete an optional survey on the use of FMT between January 2017 to September 2018 (n = 5430). A cross-sectional analysis was performed within patients who completed the survey and did not have a pouch or ostomy. Patients' demographic characteristics, disease activity and phenotype, mode of FMT delivery, and patient-reported efficacy were compared. Among 3274 eligible patients, 51 (1.6%) responded that they had an FMT in the past. Of patients undergoing FMT, 22 patients had the FMT for Patients undergoing FMT for an indication other than
Sections du résumé
BACKGROUND
BACKGROUND
There is a growing interest in the role of gut bacteria in a number of diseases and an emerging hypothesis that inflammatory bowel disease (IBD) is triggered by microbial dysbiosis in genetically susceptible individuals. Currently, fecal microbiota transplantation (FMT) is utilized for the treatment of
METHODS
METHODS
Patients enrolled in the IBD Partners cohort were offered the opportunity to complete an optional survey on the use of FMT between January 2017 to September 2018 (n = 5430). A cross-sectional analysis was performed within patients who completed the survey and did not have a pouch or ostomy. Patients' demographic characteristics, disease activity and phenotype, mode of FMT delivery, and patient-reported efficacy were compared.
RESULTS
RESULTS
Among 3274 eligible patients, 51 (1.6%) responded that they had an FMT in the past. Of patients undergoing FMT, 22 patients had the FMT for
CONCLUSIONS
CONCLUSIONS
Patients undergoing FMT for an indication other than
Identifiants
pubmed: 32421761
doi: 10.1093/crocol/otaa024
pii: otaa024
pmc: PMC7215656
doi:
Types de publication
Journal Article
Langues
eng
Pagination
otaa024Subventions
Organisme : NIDDK NIH HHS
ID : P30 DK034987
Pays : United States
Commentaires et corrections
Type : CommentIn
Informations de copyright
© 2020 Crohn’s & Colitis Foundation. Published by Oxford University Press on behalf of Crohn's & Colitis Foundation.
Références
Gastroenterology. 2015 Jul;149(1):110-118.e4
pubmed: 25836986
Gut. 1998 Jul;43(1):29-32
pubmed: 9771402
Inflamm Bowel Dis. 2011 Jan;17(1):105-11
pubmed: 20629100
Am J Gastroenterol. 2011 Dec;106(12):2133-42
pubmed: 21912437
Aliment Pharmacol Ther. 2017 Sep;46(5):479-493
pubmed: 28707337
Clin Infect Dis. 2018 Mar 19;66(7):987-994
pubmed: 29562266
Curr Opin Gastroenterol. 2013 Jan;29(1):79-84
pubmed: 23041678
United European Gastroenterol J. 2019 Jul;7(6):807-814
pubmed: 31316785
Gastroenterology. 2015 Jul;149(1):102-109.e6
pubmed: 25857665
Gut. 2008 Feb;57(2):205-10
pubmed: 17905821
Am J Gastroenterol. 2013 Apr;108(4):478-98; quiz 499
pubmed: 23439232
Inflamm Bowel Dis. 2012 Nov;18(11):2099-106
pubmed: 22287300
J Crohns Colitis. 2017 Oct 1;11(10):1180-1199
pubmed: 28486648
World J Gastroenterol. 2014 Oct 28;20(40):14805-20
pubmed: 25356041
Physiol Rev. 2010 Jul;90(3):859-904
pubmed: 20664075
Inflamm Bowel Dis. 2014 Mar;20(3):541-4
pubmed: 24451221
JAMA. 2019 Jan 15;321(2):156-164
pubmed: 30644982
Lancet. 2017 Mar 25;389(10075):1218-1228
pubmed: 28214091
Inflamm Bowel Dis. 2013 Jun;19(7):1506-13
pubmed: 23624888